The AP1B1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from HeLa cells, in which the AP1B1 gene has been disrupted. This gene encodes the ??1 subunit of adaptor protein complex 1 (AP-1), and its knockout provides a loss-of-function model to study clathrin-mediated vesicle formation and cargo sorting at the trans-Golgi network. The polyclonal format preserves population-level heterogeneity, avoiding clonal artifacts. These cells are optimized for downstream trafficking, signaling, and disease-modeling experiments.
HeLa cells originate from a human cervical adenocarcinoma and serve as a highly tractable epithelial model for cell biology studies. They feature rapid proliferation, consistent karyotype in culture, and well-characterized secretory and endocytic pathways. Their ease of transfection and compatibility with standard imaging and biochemical assays facilitate rigorous analysis of adaptor-dependent trafficking. The HeLa background thus provides a physiologically meaningful context for interrogating AP1B1 function.
The AP1B1 product, ??1, is a core subunit of the heterotetrameric AP-1 complex. Recruited to TGN membranes by ARF1 GTPase and regulated by protein kinase D and phosphatidylinositol 4-kinase, the complex recognizes sorting motifs on cargos such as M6PR and LIMP-2. It then interacts with clathrin and accessory factors like Aftiphilin and EpsinR to drive vesicle budding. AP1B1 knockout abolishes cargo selection, leading to failure of clathrin-coated vesicle formation and missorting of lysosomal hydrolases, thereby disrupting Golgi-to-endosome transport.
In HeLa cells, disruption of AP1B1 causes rerouting of lysosomal enzymes to the constitutive secretory pathway, resulting in their secretion instead of lysosomal delivery. This phenotype mimics aspects of lysosomal storage disorders and can be used to study the molecular basis of diseases such as medullary sponge kidney disease and KIDAR syndrome. Additionally, altered sorting of signaling receptors may impact cancer cell proliferation and invasiveness, making the knockout a relevant model for oncogenic trafficking.
This knockout cell population enables a range of experimental approaches including western blotting for AP1B1 and cargo proteins, immunofluorescence for Golgi/endosomal markers, co-immunoprecipitation of AP-1 subunits, pulse-chase analysis of lysosomal enzyme secretion, flow cytometry of surface receptors, and lysosomal enzyme activity assays. Applications span intracellular trafficking research, lysosomal storage disorder modeling, drug delivery pathway analysis, and CRISPR functional validation. For technical details, please contact Ascent Research.
